Background: To date, the significance of altered expression of V-set and immunoglobulin domain containing 1 (VSIG1) in gastric cancer has not yet been elucidated. Methods: We examined VSIG1 expression in 30 paired gastric cancer tissues and noncancerous gastric mucosa as well as in 5 gastric cancer cell lines by real-time PCR and Western blotting. In addition, we analyzed VSIG1 expression in 232 gastric adenocarcinoma samples by immunohistochemistry. Results: VSIG1 expression was significantly reduced at both the mRNA and protein levels in gastric cancer tissues. Immunohistochemistry revealed that VSIG1 expression was completely lost in 126 out of the 232 (54.3%) patient samples and remarkably reduced in another 106 (45.7%) patients. Negative VSIG1 expression was significantly correlated with tumor size (P ¼ 0.007), T (P ¼ 0.023), and M stage (P ¼ 0.037). Importantly, loss of VSIG1 expression was significantly correlated with poor overall survival (OS, P < 0.001) and disease-free survival (DFS, P ¼ 0.006) in gastric cancer patients. Cox regression analyses showed that VSIG1 expression was an independent predictor of OS (P ¼ 0.002) and DFS (P ¼ 0.039). Conclusions: Our findings suggest that silencing VSIG1 may play an important role in gastric carcinogenesis and that VSIG1 may serve as a prognostic marker as well as a potential therapeutic target for gastric cancer.
INTRODUCTION
Gastric cancer is the fourth most common malignancy in the world and the second leading cause of cancer-related death in humans [1] . Nearly one million new gastric cancer cases are diagnosed each year worldwide, half of which are in Eastern Asia. It is generally thought that gastric cancer results from the combinatorial effects of environmental factors and the accumulation of genetic and epigenetic disorders. Most gastric cancers emerge after a long period of chronic atrophic gastritis and intestinal metaplasia, with the single most common cause being Helicobactor pylori infection [2] . In addition, the consumption of grilled and N-nitrosamine-enriched foods is also considered to be highly correlated with gastric carcinogenesis. When clinically diagnosed, a significant number of gastric cancer patients are beyond the limits of curative resection [3] . Understanding the molecular pathways involved in gastric carcinogenesis will be critical for the improvement of diagnosis and therapy of gastric cancer.
Aberrant gene expression, including the activation of oncogenes and the inactivation of tumor suppressor genes, plays an important role in the initiation and progression of gastric cancer [4] . Thousands of genes differentially expressed between normal gastric mucosa and cancerous tissues, including those that mediate cell adhesion, have been identified using high-throughput microarray-based expression profiling [5, 6] . Cell adhesion molecules participate in numerous cell functions, for example, signal transduction, cell growth, differentiation, cell motility, and immune function [7] . In fact, changes in the expression and function of cell adhesion molecules have been implicated in all steps of tumor development and progression. These disorders cause disruption of cell-cell or cell-extracellular matrix interactions, which significantly contribute to the uncontrolled proliferation, progression, and metastasis of cancer cells. One of the classical examples is E-cadherin, a calcium-dependent cell adhesion glycoprotein encoded by the CDH1 gene, which has been shown to be exclusively expressed in epithelia and frequently silenced in carcinoma, including gastric cancer [8] [9] [10] . In contrast, overexpression of integrin b3 is correlated with poor prognosis of gastric cancer [11] .
Increasing attention has recently been paid to the role of tight junctions in carcinogenesis. Tight junctions are a characteristic feature of epithelial cells and are constructed from a complex array of integral and peripheral proteins [12] . The former include occludin, tricellulin, claudins, junctional adhesion molecules (JAMs) and Crumbs, whereas the latter comprise a wide spectrum of proteins, including the membrane-associated guanylate kinase (MAGUK) family, MAGUK inverted (MAGI) proteins, cingulin and symplekin. Two major functions defined for tight junctions are the regulation of paracellular permeability and the maintenance of cell polarity. The development of epithelial tumors is associated with a loss of cell polarity and disturbances in the structure and function of tight junctions. The down-regulation of JAM-A has been reported to be involved in the progression of clear cell renal cell carcinoma [13] and breast cancer cells [14] , whereas JAM-C promotes tumor growth and angiogenesis [15] . In gastric cancer, decreased expression of claudins-1, 4, and 11 is associated with a more malignant cancer phenotype [16] [17] [18] , while the expression of claudin-7 is increased in intestinal-type gastric cancer [19] and may cause epithelial dysfunction [20] . Coxsakievirus and adenovirus receptor (CAR), another member of the JAM family, has been reported to suppress the proliferation, migration, and invasion of gastric cancer cells, and the loss of CAR predicts poor prognosis in gastric cancer [21] . Overall, these observations underline the complex roles of tight junction proteins in gastric cancer.
V-set and immunoglobulin domain containing 1 (VSIG1), a newly discovered member of the JAM family, is widely expressed in gastric epithelia [22] . A recent microarray study showed that VSIG1 expression was reduced in both Japanese and Finnish gastric cancer tissues [23] . However, the clinical significance of such differential expression and the function of the VSIG1 protein have not yet been defined. In this study, we evaluated the expression of VSIG1 using quantitative real-time PCR, Western blotting, and immunohistochemistry. We determined its correlation with clinicopathological parameters. In addition, we identified the potential prognostic value of VSIG1 for the post-resection survival of gastric cancer patients. Mainly remnant gastric cancer. Ã Statistically significant (P < 0.05).
MATERIALS AND METHODS

Patients and Follow-Up
The clinicopathological data from 232 gastric cancer patients who underwent surgical resection at the Sun Yat-Sen University Cancer Center between 2003 and 2006 were retrospectively analyzed. Patients who met all the following eligibility criteria were included in our study: (1) diagnosis of gastric adenocarcinoma identified by histopathological examination; (2) surgical history that included gastrectomy plus lymphadenectomy (limited or extended); (3) availability of complete follow-up data; (4) no preoperative treatment, such as chemotherapy and radiotherapy; (5) no history of familial malignancy or other synchronous malignancy; (6) no recurrent gastric cancer, and (7) no death during the perioperative period. Tumor resection and D2 lymphadenectomy were performed by experienced surgeons, and the surgical procedure of radical resection, following the Japanese Gastric Cancer Association (JGCA) guidelines [24] , was similar in all patients. These patients included 159 males and 73 females, with a median age of 59 years (range: 23-85 years). Gastric cancer was primarily diagnosed by imaging (X-ray, CT, MRI, etc.), endoscopy, and biopsy. After operation, histopathological diagnosis of each tumor specimen was confirmed with hematoxylin-eosin (HE) staining in the Department of Pathology. The histopathological type and grade were determined using the criteria of the World Health Organization (WHO) classification [25] . All the gastric adenocarcinomas were graded based on their glandular differentiation degree, with Grade 1 for well-differentiated adenocarcinomas (more than 95% of tumor composed of glands), including tubular adenocarcinomas; Grade 2 for moderately differentiated adenocarcinomas (50-95% of tumor composed of glands), and Grade 3 for poorly differentiated carcinomas (49% or less of tumor composed of glands). All patients were staged according to the seventh-edition Tumor Node Metastasis (TNM) staging system of the Union for International Cancer Control (UICC) and American Joint Committee on Cancer (AJCC) [26] . Post-operative follow-up, including physical and laboratory examinations, was performed at the outpatient department every 3 months for the first 2 years, every 6 months for the 3rd to 5th years and annually thereafter until at least 5 years after the operation or until the patient died, whichever came first. The follow-up was closed in September, 2011. The median follow-up for the entire cohort was 57 months (range: 3-91 months). Overall survival (OS), defined as the time from operation to death or last follow-up, was used as a measure of prognosis. Disease-free survival (DFS) is defined as the time elapsed from operation to the date of the recurrence or distant metastasis of gastric cancer (with histopathological confirmation or imaging diagnostic evidence of tumor recurrence or metastasis); development of a second nongastric cancer (with the exception of skin basal cell carcinoma; ductal or lobular breast carcinoma in situ and cervical carcinoma in situ), or death, whichever occurred first. The characteristics of these patients are listed in Table I .
Gastric Cancer Tissues
For real-time quantitative PCR and Western blotting analyses, a total of 30 paired cancerous tissues and matched adjacent noncancerous gastric mucosa located at least 2 cm away from the cancer were collected from gastric adenocarcinoma patients undergoing gastrectomy at Sun Yat-Sen University Cancer Center between March and June, 2009. The 30 patients included 19 men and 11 women, with a median age of 53 years (range: 31-77 years). After resection, the fresh tissues were immediately frozen in liquid nitrogen and stored at À808C. Both the cancerous and noncancerous gastric mucosa tissues were verified by histopathological examination. For immunohistochemical staining, formalin-fixed, paraffin-embedded primary gastric adenocarcinoma samples were collected from the 232 patients mentioned above and stored at room temperature. HE slides from these patients were viewed under a light microscope by a pathologist and 5-mm thick tissue sections were cut from corresponding blocks containing representative tumor regions. The research was approved by the Ethical Committee of Sun Yat-Sen University Cancer Center, and informed consent was obtained from each patient.
Cell Culture
Gastric cancer cell lines SGC7901, MGC803, HGC27, MKN45, and AGS were obtained from the Committee of Type Culture Collec- 
RNA Extraction and Quantitative Real-Time PCR
Total RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's protocol. Then, 2 mg of RNA was reverse transcribed into first-strand cDNA by M-MLV Reverse Transcriptase (Promega, Madison, WI) according to the manufacturer's instructions. VSIG1 and GAPDH were amplified by quantitative real-time PCR using the following primers: VSIG1 forward:
0 . Gene-specific amplification was performed in an ABI 7900HT real-time PCR system (Life Technologies, Carlsbad, CA) with a 15-ml PCR mix containing 0.5 ml of cDNA, 7.5 ml of 2Â SYBR Green master mix (Invitrogen), and 200 nM of the appropriate primers. The mix was preheated at 958C for 10 min and then amplified in 45 cycles of 958C for 30 sec and 608C for 1 min. The resolution curve was measured at 958C for 15 sec, 608C for 15 sec, and 958C for 15 sec. The C t (threshold cycle) value of each sample was calculated, and the relative expression of VSIG1 mRNA was normalized to the GAPDH value (2 ÀDCt method).
Western Blotting Analysis
Homogenized tissues were lysed in RIPA lysis buffer, and the lysates were harvested by centrifugation (12,000 rpm) at 48C for 30 min. Next, the protein samples (20 mg) were separated by electrophoresis in a 12% SDS-PAGE and were transferred onto a polyvinylidene fluoride membrane. The membrane was placed in 5% nonfat milk for 1 hr to block the nonspecific binding sites and was then incubated with a sheep anti-human VSIG1 antibody (1:1,000, R&D Systems, Minneapolis, MN) at 48C overnight. After washing four times in Tris-buffered saline with Tween-20, the membrane was probed with a horseradish peroxidase (HRP)-conjugated rabbit antisheep IgG antibody (1:2,000, Proteintech Group, Chicago, IL) at 378C for 60 min. After four washes, the bands were detected with the enhanced chemiluminescence reagent (Cell Signaling Technology, Danvers, MA). Band density was measured with ImageJ software (National Institutes of Health, Bethesda, MD) and was standardized to that of GAPDH detected using mouse anti-human GAPDH monoclonal antibody (Shanghai Kangchen, Shanghai, China).
Immunohistochemistry
After deparaffinization with dimethylbenzene, the tissue sections were rehydrated through 100%, 95%, 90%, 80%, and 70% ethanol. After three washes in phosphate-buffered saline (PBS), the slides were boiled in antigen retrieval buffer containing 1 mM of disodium ethylenediaminetetraacetic acid (pH ¼
0 -diaminobenzidine (DAB) solution was added to the sections to develop the color, followed by counterstaining with hematoxylin. For negative controls, adjacent sections were processed as described above except that they were incubated overnight at 48C in blocking solution without the primary antibody.
The intensity and extent of VSIG1 immunostaining were evaluated for all samples under double-blinded conditions. In brief, the percentage of positive staining was scored as 0 (0-9%), 1 (10-25%), 2 (26-50%), or 3 (51-100%), and the intensity as 0 (no staining), 1 (weak staining), 2 (moderate staining), or 3 (dark staining). The total score was calculated as the product of intensity and extent, ranging from 0 to 9. The expression level of VSIG1 was defined as following: ''À'' (negative, score 0), ''þ'' (weakly positive, score 1-3), ''þþ'' (positive, score 4-6), ''þþþ'' (strongly positive, score 7-9).
Statistical Analysis
Differences in mRNA expression between cancerous and normal gastric tissues were evaluated with the Wilcoxon signed ranks test, whereas protein expression levels were compared with paired Student's t-test. A chi-squared test was used to analyze the relationships between VSIG1 expression and various clinicopathological parameters. A Kaplan-Meier survival function was calculated and compared with a log-rank test. A Cox proportional hazard regression model was used for univariate and multivariate analyses to explore the effects of the clinicopathological variables and VSIG1 expression on survival. SPSS 17.0 software (SPSS, Chicago, IL) was used for all statistical analyses, and P < 0.05 was considered significant.
RESULTS
VSIG1 mRNA Expression
We first measured VSIG1 mRNA levels in 30 paired cancerous and normal gastric tissues using quantitative real-time PCR. As shown in Figure 1 , the median VSIG1 mRNA expression level was significantly lower in gastric cancer tissues than the corresponding normal gastric tissues (P ¼ 0.021), and 76% of the subjects (23/30) displayed lower VSIG1 mRNA expression in cancer tissues.
VSIG1 Protein Expression
We then determined VSIG1 protein levels in resected gastric cancer samples and cell lines by Western blotting. Consistent with the quantitative real-time PCR results, out of a total of 26 paired cancerous and adjacent normal tissues, VSIG1 expression was reduced in cancerous tissues relative to their respective adjacent normal tissues in 18 cases (P ¼ 0.033, Fig. 2A,B) . No VSIG1 expression was detected in the 5 gastric cancer cell lines (Fig. 2C ).
Immunohistochemical Analysis of VSIG1 Expression in Gastric Cancer and Its Relationship With the Clinicopathological Parameters
To validate the above findings and investigate the clinicopathological and prognostic roles of VSIG1 expression, we performed immunohistochemical analyses of the 232 paraffin-embedded gastric cancer tissue blocks. Overall, 126 of 232 (54.3%) cases showed negative VSIG1 expression in cancerous tissues (Fig. 3B) , whereas 106 (45.7%) cases showed positive immunostaining (Fig. 3C,D) . Normal gastric mucosa showed the strongest VSIG1 positive staining (Fig. 3A) . As listed in Table I , the loss of VSIG1 expression was significantly correlated with tumor size (P ¼ 0.007), depth of tumor infiltration (T stage, P ¼ 0.023), and distant metastasis (M stage, P ¼ 0.037), but not with age, gender, tumor locus, or local lymph node metastasis (N stage).
VSIG1 Expression and clinical Outcome
As shown in Figure 4 , patients with VSIG1-negative gastric cancer showed shorter OS (P < 0.001, log-rank test, Fig. 4A ) and poorer DFS (P ¼ 0.006, log-rank test, Fig. 4B ) than those with VSIG1-positive gastric cancer. Univariate Cox regression analyses revealed that OS significantly decreased with larger tumor size (P ¼ 0.009), higher T stage (P < 0.001), higher N stage (P < 0.001), higher M stage (P < 0.001), and negative VSIG1 expression (P < 0.001), while DFS significantly decreased with higher T stage (P ¼ 0.047), higher N stage (P ¼ 0.016), higher M stage (P ¼ 0.035), and negative VSIG1 expression (P ¼ 0.007; Table II) . Furthermore, multivariate Cox regression analyses confirmed T stage (P ¼ 0.023), N stage (P < 0.001), M stage (P < 0.001), and VSIG1 expression (P ¼ 0.002) as significant independent predictors of the OS of gastric cancer patients, whereas M stage (P ¼ 0.032) and VSIG1 expression (P ¼ 0.039) were significant independent prognostic factors for DFS (Table III) . Fig. 4 . Kaplan-Meier survival curves of gastric cancer patients (n ¼ 232) after gastrectomy. Patients with VSIG1-negative gastric cancer showed both significantly worse OS (A) and DFS (B) than those with VSIG1-positive gastric cancer (log-rank test, P < 0.001 and P ¼ 0.006, respectively).
DISCUSSION
Gastric cancer remains one of the most deadly human malignancies. Even with advances in diagnosis and therapy, the prognosis for gastric cancer is still dismal [27] . The clinical outcome of gastric cancer is determined by local tumor growth, invasion, and distant metastasis [3] , all of which involve dysfunctional cell adhesion [7] . Although many previous studies have addressed the reorganization of certain adherent junction proteins, such as the E-cadherin/b-catenin complex [8] , the roles of tight junctions in gastric cancer progression are only now beginning to be revealed. Tight junction proteins are now considered active regulators of cell proliferation, differentiation, migration, and gene transcription [12] .
JAMs are type I tight junction proteins characterized by two extracellular immunoglobulin (Ig)-like folds with intramolecular disulfide bonds, a single transmembrane domain, and a cytoplasmic domain containing a PDZ-binding motif [12] . These proteins are classified as C1, C2, V, and I types based on their similarity to the constant and variable Ig regions. Although members of this protein family have been previously studied in several kinds of malignancies [13, 14] , the expression and roles of JAMs in gastric cancer are rarely investigated, with the exception of CAR, which is expressed in all the examined normal gastric mucosa samples (175/175), but silenced in 87 out of the 196 (44.4%) gastric cancer samples [21] . In addition, the expression of CAR is completely lost in KATO III and MKN38 gastric cell lines and reduced obviously in the MKN45 cell line, whereas AGS cell line shows robust CAR expression. In this study, we examined the mRNA and protein expression levels of VSIG1, a V type JAM member, in paired gastric cancer tissues and nonmalignant gastric mucosa. Consistent with the findings of Scanlan et al. [22] and the microarray study of Junnila et al. [23] , we found that both the mRNA and protein levels of VSIG1 were significantly lower in cancerous tissues than the respective noncancerous mucosa. In addition, no VSIG1 expression was detected in five gastric cancer cell lines.
To further validate this reduction of VSIG1 expression in gastric cancer, we performed an immunohistochemical analysis with a sheep anti-hVSIG1 antibody. In agreement with the Western blotting results, more than 50% of the cancer samples displayed negative VISG1 immunostaining. Furthermore, among the VSIG1-positive cases, most showed lower VSIG1 immunostaining relative Mainly remnant gastric cancer. Ã Statistically significant (P < 0.05).
to the noncancerous mucosa. Scanlan et al. [22] previously reported a positive VSIG1 immunostaining rate of only 29% in gastric cancer samples (5/17) . This discrepancy may stem from the difference in sample size, as our study assessed a much larger group of patients (232 cases). We also found that the loss of VSIG1 expression was associated with higher T stage and larger tumor size, implying that the absence of VSIG1 might promote tumor growth and invasion. In addition, we detected lower VSIG1 immunostaining in stage M1 compared with M0 gastric cancer tissues, suggesting that decreased VSIG1 expression may facilitate tumor metastasis. These findings collectively indicate an important role for VSIG1 in the growth and metastasis of gastric cancer. Whether the loss of VSIG1 is a cause or consequence of tumor progression and metastasis, however, remains unclear. Considering that VSIG1 is a cell adhesion protein of the JAM family, our data support the concept that disrupted intercellular adhesion is a prerequisite for tumor growth and metastasis, in accordance with the role described for E-cadherin in gastric cancer [28, 29] . Indeed, other JAM family members have been shown to function as tumor suppressors [15] . Anders et al. [21] found that enforced ectopic expression of CAR inhibited the proliferation, migration, and invasion of gastric cell lines, whereas RNAi-mediated CAR knockdown had opposite effects. Collectively, these data have suggested important biological roles of JAMs in gastric carcinogenesis.
Kaplan-Meier survival analyses revealed a significant correlation between the loss of VSIG1 expression and poor survival of gastric cancer patients after gastrectomy. A Cox regression model further demonstrated that the VSIG1 expression level was an independent risk factor for both OS and DFS, suggesting that VSIG1 may serve as a prognostic biomarker for gastric cancer patients after surgery. These data are in accordance with the concept of the correlation between disturbed cell adhesion and poor prognosis in gastric cancer [30] . In particular, it is widely accepted that the loss of E-cadherin expression is associated with unfavorable survival in gastric cancer patients [29] . However, only a few studies have investigated the association between the expression of tight junction proteins, especially the JAM family proteins, and gastric cancer prognosis. Two previous studies reported that high expression of either claudin-4 or claudin-18 was significantly correlated with a better prognosis [31, 32] . For JAM family members, only one report to date has correlated CAR expression with the gastric cancer patient survival [21] . Our finding that the loss of VSIG1 expression in gastric cancer is associated with more malignant phenotypes and a worse prognosis suggests that this tight junction protein may play a tumor suppressor role in gastric cancer cells.
VSIG1 expression is enriched in the testis, and it was reported that the Ig domain of VSIG1 interacts with Sertoli cell membrane protein [33] . The VSIG1 molecule belongs to the JAM family, which contains two Ig-like domains in their extracellular area [34] . The roles of other members of this family have been studied in breast cancer and renal cancer [13, 14] . In gastric cancer, CAR, a member of the JAM family, has been shown to repress the proliferation, migration, and invasion of gastric cancer cells [21] . Nevertheless, there is no report concerning the prognostic roles of VSIG1 in cancer prior to this study. Considering the structural similarity and sequence homology of this protein family, it is possible that VSIG1 may suppress the gastric carcinogenesis in a similar manner as CAR and JAM-A. While our study has demonstrated a correlation between VSIG1 expression and gastric cancer stage and prognosis, the mechanism involved in biological function of VSIG1 in gastric cancer warranties further investigation.
CONCLUSIONS
In the present study, we report the loss of VSIG1 expression in gastric cancers and show that the absence of this protein is correlated with a more malignant phenotype and a worse clinical outcome. Our findings contribute to the current understanding on the role of tight junctions in gastric cancer. To our best knowledge, the data generated in this study represent the first report correlating the presence of VSIG1 with clinicopathological characteristics as well as with the OS and DFS of gastric cancer patients. 
